RT Generic
T1 An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
A1 Kasper, B.
A1 Baumgarten, C.
A1 Garcia, J.
A1 Bonvalot, S.
A1 Haas, R.
A1 Haller, F.
A1 Hohenberger, P.
A1 Penel, N.
A1 Messiou, C.
A1 van der Graaf, W. T.
A1 Gronchi, A.
A1 Desmoid Working Grp, 
K1 desmoid
K1 aggressive fibromatosis
K1 EORTC/STBSG
K1 patient advocacy groups
K1 SPAEN
K1 treatment algorithm
K1 Advanced aggressive fibromatosis
K1 Phase-ii trial
K1 Soft-tissue
K1 Local recurrence
K1 Abdominal-wall
K1 1st-line management
K1 Surgical resection
K1 Prognostic-factors
K1 Treatment options
K1 See policy
AB Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.
PB Oxford univ press
SN 0923-7534
YR 2017
FD 2017-10-01
LK https://hdl.handle.net/10668/27274
UL https://hdl.handle.net/10668/27274
LA en
DS RISalud
RD Apr 17, 2025